AACR: Pan-AKT Inhibitor ARQ092 Shows Promise in Solid Tumors in First-in-Human Trial

The pan-AKT inhibitor ARQ092 was shown to be well-tolerated, avoiding dose-limiting toxicities that often haunt inhibitors of AKT signaling, according to results presented at the 2013 AACR meeting.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news